Hereditary breast and ovarian cancer susceptibility genes (review).

Women with hereditary breast and ovarian cancer (HBOC) syndrome represent a unique group who are diagnosed at a younger age and result in an increased lifetime risk for developing breast, ovarian and other cancers. This review integrates recent progress and insights into the molecular basis that underlie the HBOC syndrome. A review of English language literature was performed by searching MEDLINE published between January 1994 and October 2012. Mutations and common sequence variants in the BRCA1 and BRCA2 (BRCA) genes are responsible for the majority of HBOC syndrome. Lifetime cancer risks in BRCA mutation carriers are 60-80% for breast cancer and 20-40% for ovarian cancer. Mutations in BRCA genes cannot account for all cases of HBOC, indicating that the remaining cases can be attributed to the involvement of constitutive epimutations or other cancer susceptibility genes, which include Fanconi anemia (FA) cluster (FANCD2, FANCA and FANCC), mismatch repair (MMR) cluster (MLH1, MSH2, PMS1, PMS2 and MSH6), DNA repair cluster (ATM, ATR and CHK1/2), and tumor suppressor cluster (TP53, SKT11 and PTEN). Sporadic breast cancers with TP53 mutations or epigenetic silencing (hypermethylation), ER- and PgR-negative status, an earlier age of onset and high tumor grade resemble phenotypically BRCA1 mutated cancers termed 'BRCAness', those with no BRCA mutations but with a dysfunction of the DNA repair system. In conclusion, genetic or epigenetic loss-of-function mutations of genes that are known to be involved in the repair of DNA damage may lead to increased risk of developing a broad spectrum of breast and ovarian cancers.

[1]  O. Díez,et al.  Low prevalence of SLX4 loss-of-function mutations in non-BRCA1/2 breast and/or ovarian cancer families , 2012, European Journal of Human Genetics.

[2]  A. Schetter,et al.  Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS , 2014, Breast Cancer.

[3]  L. G. Rossato,et al.  Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil , 2012, Genetics and molecular biology.

[4]  A. Tinker,et al.  The role of PARP inhibitors in the treatment of ovarian carcinomas. , 2012, Current pharmaceutical design.

[5]  J. Ford,et al.  Genetic Testing by Cancer Site: Stomach , 2012, Cancer journal.

[6]  K. Aittomäki,et al.  Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases , 2012, Breast Cancer Research.

[7]  M. Yaffe,et al.  Long-term results of screening with magnetic resonance imaging in women with BRCA mutations , 2012, British Journal of Cancer.

[8]  Challenges in the management of a patient with Cowden syndrome: case report and literature review , 2012, Hereditary cancer in clinical practice.

[9]  L. Wiesmüller,et al.  BRCA1-mediated repression of mutagenic end-joining of DNA double-strand breaks requires complex formation with BACH1. , 2012, The Biochemical journal.

[10]  B. Karlan,et al.  Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Gord Glendon,et al.  Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .

[12]  J. Thigpen.  Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer , 2012 .

[13]  I. Chirivella González,et al.  Low penetrance alleles as risk modifiers in familial and sporadic breast cancer , 2012, Familial cancer.

[14]  Douglas F. Easton,et al.  Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. , 2012, JAMA.

[15]  F. Roviello,et al.  Frequency of CDH1 germline mutations in gastric carcinoma coming from high- and low-risk areas: metanalysis and systematic review of the literature , 2012, BMC Cancer.

[16]  Constantin Sajdik,et al.  Genetic polymorphisms in AURKA and BRCA1 are associated with breast cancer susceptibility in a Chinese Han population , 2011, The Journal of pathology.

[17]  Jeong-Won Lee,et al.  Synchronous gynecologic malignancy and preliminary results of Lynch syndrome , 2011, Journal of gynecologic oncology.

[18]  C. Isaacs,et al.  BRCA Mutation Testing in Determining Breast Cancer Therapy , 2011, Cancer journal.

[19]  L. Salmena,et al.  BRCA1 and BRCA2 mutations and breast cancer. , 2011, Discovery medicine.

[20]  Susan L. Neuhausen,et al.  RAD51C Germline Mutations in Breast and Ovarian Cancer Cases from High-Risk Families , 2011, PloS one.

[21]  J. Schleutker,et al.  RAD51C is a susceptibility gene for ovarian cancer. , 2011, Human molecular genetics.

[22]  L. Niedernhofer,et al.  ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer , 2011, Pharmacogenomics and personalized medicine.

[23]  Kwok-Kin Wong,et al.  COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION , 2011, Nature Medicine.

[24]  D. Bodurka,et al.  Satisfaction with ovarian carcinoma risk‐reduction strategies among women at high risk for breast and ovarian carcinoma , 2011, Cancer.

[25]  M. Yaffe,et al.  Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Wei Zheng,et al.  Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. , 2011, The Lancet. Oncology.

[27]  Hai Hu,et al.  Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice , 2011, Breast Cancer Research.

[28]  D. Aoki,et al.  Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome , 2011, Current genomics.

[29]  J. Schleutker,et al.  Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals , 2011, Breast Cancer Research.

[30]  P. Brown,et al.  Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[31]  S. Mok,et al.  Microscopic and Early-Stage Ovarian Cancers in BRCA1/2 Mutation Carriers: Building a Model for Early BRCA-Associated Tumorigenesis , 2011, Cancer Prevention Research.

[32]  G. Mills,et al.  Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer , 2011, Clinical Cancer Research.

[33]  P. Glazer,et al.  Functional and physical interaction between the mismatch repair and FA-BRCA pathways. , 2011, Human molecular genetics.

[34]  L. Shulman,et al.  A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk , 2011 .

[35]  A. Sokolenko,et al.  Hereditary Breast-Ovarian Cancer Syndrome in Russia , 2010, Acta naturae.

[36]  Å. Borg,et al.  Genetic profiles distinguish different types of hereditary ovarian cancer. , 2010, Oncology reports.

[37]  Dieter Niederacher,et al.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.

[38]  Joseph P. Costantino,et al.  Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer , 2010, Cancer Prevention Research.

[39]  Hiroshi Honda,et al.  Detection of non-palpable breast cancer in asymptomatic women by using unenhanced diffusion-weighted and T2-weighted MR imaging: comparison with mammography and dynamic contrast-enhanced MR imaging , 2010, European Radiology.

[40]  M. Federico,et al.  Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer , 2010, BMC Cancer.

[41]  G. Tolis,et al.  Reproductive disturbances in multiple neuroendocrine tumor syndromes. , 2009, Endocrine-related cancer.

[42]  Roberto Giugliani,et al.  Genomic rearrangements in BRCA1 and BRCA2: A literature review , 2009, Genetics and molecular biology.

[43]  Alfons Meindl,et al.  Breast cancer susceptibility: current knowledge and implications for genetic counselling , 2009, European Journal of Human Genetics.

[44]  Junjie Chen,et al.  PALB2 is an integral component of the BRCA complex required for homologous recombination repair , 2009, Proceedings of the National Academy of Sciences.

[45]  P. Nederlof,et al.  High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. , 2009, Cancer research.

[46]  A. Godwin,et al.  Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management , 2009, Molecular oncology.

[47]  Ling-ling Jiang,et al.  Induction of G2/M arrest by pseudolaric acid B is mediated by activation of the ATM signaling pathway , 2009, Acta Pharmacologica Sinica.

[48]  R. Broaddus,et al.  Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[49]  Stephanie A Cohen,et al.  The prevalence of BRCA1 mutations among young women with triple-negative breast cancer , 2009, BMC Cancer.

[50]  S. Powell,et al.  Biomarkers and Mechanisms of FANCD2 Function , 2008, Journal of biomedicine & biotechnology.

[51]  R. Scott,et al.  The VEGF_936_C>T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. , 2008, Cancer letters.

[52]  A. Godwin,et al.  Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. , 2008, Cancer research.

[53]  Chen-Yang Shen,et al.  Breast Cancer Risk Is Associated with the Genes Encoding the DNA Double-Strand Break Repair Mre11/Rad50/Nbs1 Complex , 2007, Cancer Epidemiology Biomarkers & Prevention.

[54]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[55]  Tom Walsh,et al.  Ten genes for inherited breast cancer. , 2007, Cancer cell.

[56]  A. D’Andrea,et al.  Chk1-Mediated Phosphorylation of FANCE Is Required for the Fanconi Anemia/BRCA Pathway , 2007, Molecular and Cellular Biology.

[57]  D. Fishman,et al.  Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. , 2007, The Lancet. Oncology.

[58]  B. Friedenson,et al.  The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers , 2007, BMC Cancer.

[59]  J. Damborský,et al.  High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic , 2007, BMC Medical Genetics.

[60]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[61]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[62]  J. Fridlyand,et al.  Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer. , 2006, Genetic testing.

[63]  A. Whittemore,et al.  Oral Contraceptive Use and Risk of Early-Onset Breast Cancer in Carriers and Noncarriers of BRCA1 and BRCA2 Mutations , 2005, Cancer Epidemiology Biomarkers & Prevention.

[64]  M. Nooij,et al.  Survival of Patients with Ovarian Cancer due to a Mismatch Repair Defect , 2005, Familial Cancer.

[65]  J. Visvader,et al.  Frequency of the ATM IVS10-6T→G variant in Australian multiple-case breast cancer families , 2004, Breast Cancer Research.

[66]  G. Lenoir,et al.  Hereditary breast cancer and family cancer syndromes , 2004, World Journal of Surgery.

[67]  O. Olopade,et al.  Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. , 2001, Pharmacogenetics.

[68]  A. Sood,et al.  The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.